|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PLEKHH3 |
Gene summary for PLEKHH3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PLEKHH3 | Gene ID | 79990 |
| Gene name | pleckstrin homology, MyTH4 and FERM domain containing H3 | |
| Gene Alias | PLEKHH3 | |
| Cytomap | 17q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q7Z736 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79990 | PLEKHH3 | HCC1_Meng | Human | Liver | HCC | 6.72e-29 | -1.71e-02 | 0.0246 |
| 79990 | PLEKHH3 | HCC2_Meng | Human | Liver | HCC | 1.79e-24 | 1.75e-01 | 0.0107 |
| 79990 | PLEKHH3 | Pt13.b | Human | Liver | HCC | 1.34e-03 | 1.69e-01 | 0.0251 |
| 79990 | PLEKHH3 | S014 | Human | Liver | HCC | 8.53e-06 | 4.23e-01 | 0.2254 |
| 79990 | PLEKHH3 | S015 | Human | Liver | HCC | 2.70e-05 | 4.49e-01 | 0.2375 |
| 79990 | PLEKHH3 | S016 | Human | Liver | HCC | 3.04e-08 | 4.41e-01 | 0.2243 |
| 79990 | PLEKHH3 | S027 | Human | Liver | HCC | 7.72e-06 | 5.69e-01 | 0.2446 |
| 79990 | PLEKHH3 | S028 | Human | Liver | HCC | 1.60e-07 | 5.21e-01 | 0.2503 |
| 79990 | PLEKHH3 | C04 | Human | Oral cavity | OSCC | 2.54e-02 | 1.28e-01 | 0.2633 |
| 79990 | PLEKHH3 | C21 | Human | Oral cavity | OSCC | 1.65e-07 | 2.33e-01 | 0.2678 |
| 79990 | PLEKHH3 | C30 | Human | Oral cavity | OSCC | 2.69e-26 | 1.04e+00 | 0.3055 |
| 79990 | PLEKHH3 | C38 | Human | Oral cavity | OSCC | 1.76e-06 | 8.32e-01 | 0.172 |
| 79990 | PLEKHH3 | C43 | Human | Oral cavity | OSCC | 1.41e-05 | 2.19e-01 | 0.1704 |
| 79990 | PLEKHH3 | C46 | Human | Oral cavity | OSCC | 4.08e-17 | 4.61e-01 | 0.1673 |
| 79990 | PLEKHH3 | C51 | Human | Oral cavity | OSCC | 8.03e-04 | 3.09e-01 | 0.2674 |
| 79990 | PLEKHH3 | C57 | Human | Oral cavity | OSCC | 1.39e-04 | 2.50e-01 | 0.1679 |
| 79990 | PLEKHH3 | C06 | Human | Oral cavity | OSCC | 2.20e-02 | 7.35e-01 | 0.2699 |
| 79990 | PLEKHH3 | C08 | Human | Oral cavity | OSCC | 1.79e-12 | 3.46e-01 | 0.1919 |
| 79990 | PLEKHH3 | C09 | Human | Oral cavity | OSCC | 4.95e-03 | 1.28e-01 | 0.1431 |
| 79990 | PLEKHH3 | LN22 | Human | Oral cavity | OSCC | 7.27e-09 | 7.50e-01 | 0.1733 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PLEKHH3 | SNV | Missense_Mutation | novel | c.2057N>A | p.Gly686Glu | p.G686E | Q7Z736 | protein_coding | deleterious(0.03) | possibly_damaging(0.829) | TCGA-A7-A56D-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| PLEKHH3 | SNV | Missense_Mutation | novel | c.1310N>A | p.Leu437Gln | p.L437Q | Q7Z736 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PLEKHH3 | insertion | Frame_Shift_Ins | novel | c.2278_2279insGTCATTCAGTCGCTCCAGGAGGTAGGAG | p.Ser760CysfsTer66 | p.S760Cfs*66 | Q7Z736 | protein_coding | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| PLEKHH3 | insertion | In_Frame_Ins | novel | c.1311_1312insAAAAGCAAAAGAGGAAAAGAGGGAGAA | p.Leu437_Gly438insLysSerLysArgGlyLysGluGlyGlu | p.L437_G438insKSKRGKEGE | Q7Z736 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| PLEKHH3 | SNV | Missense_Mutation | rs777329515 | c.2257N>A | p.Glu753Lys | p.E753K | Q7Z736 | protein_coding | tolerated(1) | benign(0.015) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| PLEKHH3 | SNV | Missense_Mutation | c.346C>T | p.Pro116Ser | p.P116S | Q7Z736 | protein_coding | tolerated(0.15) | benign(0) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| PLEKHH3 | SNV | Missense_Mutation | c.1172N>T | p.Ser391Leu | p.S391L | Q7Z736 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| PLEKHH3 | SNV | Missense_Mutation | novel | c.562G>A | p.Glu188Lys | p.E188K | Q7Z736 | protein_coding | tolerated(0.32) | benign(0.026) | TCGA-VS-A9UC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| PLEKHH3 | SNV | Missense_Mutation | rs137859811 | c.1129C>T | p.Arg377Trp | p.R377W | Q7Z736 | protein_coding | tolerated(0.19) | benign(0.067) | TCGA-VS-A9UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PLEKHH3 | SNV | Missense_Mutation | c.1417N>C | p.Glu473Gln | p.E473Q | Q7Z736 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-WL-A834-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |